Pamgene International B.V.


Provider of peptide microarray-based kinome profiling and associated analysis services for biomarker discovery, preclinical drug research and development of blood-based diagnostic tests. Offers laboratory assay services, custom peptide-array design and bioinformatics for kinase-signaling and patient stratification studies, and collaborates with academic and industry partners on translational and toxicology projects.

Industries

N/A

Nr. of Employees

small (1-50)


Products

Peptide microarray kinase activity profiling platform

Laboratory platform that measures peptide phosphorylation patterns to profile kinase activity across samples; includes peptide arrays, flow-based assay workflow and associated analysis software.


Services

Laboratory-based in‑vitro diagnostic assay services generating phosphorylation profiles from blood and tissue samples for biomarker studies and diagnostic test validation under a certified quality system.

Custom kinome profiling projects including ex vivo drug panels, target-identification studies and kinome analysis across cell lines, PDX/xenografts and alternative models to support lead optimization and translational research.

Analytical services to infer upstream kinases, perform pathway/network analysis and build predictive models from peptide-array phosphorylation data using public PTM databases and in‑house workflows.

Expertise Areas

  • Kinase activity profiling
  • Biomarker discovery and validation
  • Blood-based diagnostic assay development
  • Preclinical drug screening and target discovery
  • Show More (4)

Key Technologies

  • Peptide microarray kinase assays
  • Kinome profiling (PTK and STK)
  • PBMC-based phosphorylation assays
  • Kinase–substrate inference using PTM databases
  • Show More (4)

News & Updates

Summary white paper mining AACR abstracts (2004–2013) reporting trends in small-molecule kinase inhibitor research, including numbers of compounds and frequently targeted kinases.

Certificate of Approval by Lloyd’s Register for ISO 13485:2016 Quality Management System enabling provision of in‑vitro diagnostic assay services.

Announced closing of a €13 million Series A financing round to advance deployment of diagnostic blood tests for cancer patients treated with immunotherapy.

Awarded European Innovation Council funding to develop and market a blood-based immunotherapy guidance test.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.